前瞻性研究:系列18F-FDG PET与18F-氟化物PET预测骨优势型转移性乳腺癌患者骨相关事件时间、进展时间与生存
该前瞻性研究纳入28例骨优势型转移性乳腺癌患者,在新治疗前及约4个月后行18F-FDG PET和18F-NaF PET,评估系列PET参数对骨相关事件时间(tSRE)、进展时间(TTP)和总生存(OS)的预测价值。结果显示18F-FDG PET参数变化可预测tSRE和TTP但不预测OS,mPERCIST评估骨病灶可能有助于疗效评估,值得在多中心前瞻性试验中验证;18F-NaF PET与OS相关但对TTP或tSRE无预测价值。
要点
- 第二时间点18F-FDG SULpeak较高预测更短tSRE(P<0.001)和TTP(P=0.044)。
- 18F-FDG PET mPERCIST评估中,缓解者(完全缓解、部分缓解或疾病稳定)的tSRE和TTP长于进展者(分别为P=0.007、0.028)。
- 18F-NaF PET最多5个病灶摄取增加与更长OS相关(P=0.027),但对TTP或tSRE无预测价值。
核心结论
- 治疗期间18F-FDG PET参数变化可预测tSRE和TTP,但不预测OS。
- 骨病灶的mPERCIST评估可能有助于评估治疗反应,值得在多中心前瞻性试验中评估。
- 系列18F-NaF PET与OS相关,但对骨优势型转移性乳腺癌的TTP或tSRE无预测价值。
研究设计与样本
- 前瞻性研究,纳入28例骨优势型转移性乳腺癌患者,在新治疗开始前(scan1)及约4个月前后再次(scan2)行18F-FDG PET和18F-NaF PET。
- 对单个指标病灶及最多5个最优势病灶记录SUVmax和瘦体重校正标准化摄取值(SULpeak)。
- tSRE、TTP和OS的评估独立于PET图像,采用单变量Cox回归检验临床终点与PET指标的相关性,并应用mPERCIST。
- 按mPERCIST比较完全缓解+部分缓解+疾病稳定与进展两类反应组对tSRE、TTP和OS的生存曲线。
主要发现
- 第二时间点18F-FDG SULpeak较高预测更短tSRE(P<0.001)和TTP(P=0.044)。
- 第二时间点18F-FDG SUVmax较高预测更短tSRE(P<0.001)。
- 使用scan1时指标病灶18F-FDG SUVmax加上两次扫描间最多5个病灶SUVmax差值构建的多变量模型可预测tSRE和TTP。
- 在24例可经18F-FDG PET mPERCIST评估的患者中,缓解者(完全缓解、部分缓解或疾病稳定)的tSRE和TTP长于进展者(分别为P=0.007、0.028),生存改善呈趋势(P=0.1)。
- 两次扫描间最多5个病灶18F-NaF PET摄取增加与更长OS相关(P=0.027)。
关键数值与推荐
- 第二时间点18F-FDG SULpeak较高预测更短tSRE(P<0.001)和TTP(P=0.044)。
- 第二时间点18F-FDG SUVmax较高预测更短tSRE(P<0.001)。
- mPERCIST评估中,缓解者(完全缓解、部分缓解或疾病稳定)对比进展者:tSRE P=0.007,TTP P=0.028,OS P=0.1。
- 18F-NaF PET两次扫描间最多5个病灶摄取增加与更长OS相关(P=0.027)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为骨病灶的mPERCIST评估可能有助于评估治疗反应。
- 作者认为mPERCIST评估值得在多中心前瞻性试验中评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Assessing therapy response of breast cancer bone metastases is challenging. In retrospective studies, serial 18F-FDG PET was predictive of time to skeletal-related events (tSRE) and time to progression (TTP). 18F-NaF PET improves bone metastasis detection compared with bone scanning. We prospectively tested 18F-FDG PET and 18F-NaF PET to predict tSRE, TTP, and overall survival (OS) in patients with bone-dominant metastatic breast cancer (MBC). Methods: Patients with bone-dominant MBC were imaged with 18F-FDG PET and 18F-NaF PET before starting new therapy (scan1) and again at a range of times centered around approximately 4 mo later (scan2). Maximum standardized uptake value (SUVmax) and lean body mass adjusted standardized uptake (SULpeak) were recorded for a single index lesion and up to 5 most dominant lesions for each scan. tSRE, TTP, and OS were assessed exclusive of the PET images. Univariate Cox regression was performed to test the association between clinical endpoints and 18F-FDG PET and 18F-NaF PET measures. mPERCIST (Modified PET Response Criteria in Solid Tumors) were also applied. Survival curves for mPERCIST compared response categories of complete response+partial response+stable disease versus progressive disease for tSRE, TTP, and OS. Results: Twenty-eight patients were evaluated. Higher 18F-FDG SULpeak at scan2 predicted shorter time to tSRE (P = <0.001) and TTP (P = 0.044). Higher 18F-FDG SUVmax at scan2 predicted a shorter time to tSRE (P = <0.001). A multivariable model using 18F-FDG SUVmax of the index lesion at scan1 plus the difference in SUVmax of up to 5 lesions between scans was predictive for tSRE and TTP. Among 24 patients evaluable by 18F-FDG PET mPERCIST, tSRE and TTP were longer in responders (complete response, partial response, or stable disease) than in nonresponders (progressive disease) (P = 0.007, 0.028, respectively), with a trend toward improved survival (P = 0.1). An increase in the uptake between scans of up to 5 lesions by 18F-NaF PET was associated with longer OS (P = 0.027). Conclusion: Changes in 18F-FDG PET parameters during therapy are predictive of tSRE and TTP, but not OS. mPERCIST evaluation in bone lesions may be useful in assessing response to therapy and is worthy of evaluation in multicenter, prospective trials. Serial 18F-NaF PET was associated with OS but was not useful for predicting TTP or tSRE in bone-dominant MBC.
引用
- Peterson LM, O'Sullivan J, Wu QV, et al. Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer. J Nucl Med. 2018. PMID: 29748233. doi:10.2967/jnumed.118.211102
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。